- Home
- TRML vs NXP Comparison
TRML vs NXP Comparison
Compare TRML & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- NXP
- Stock Information
- Founded
- TRML 2021
- NXP 1992
- Country
- TRML United States
- NXP United States
- Employees
- TRML N/A
- NXP N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- TRML Health Care
- NXP Finance
- Exchange
- TRML Nasdaq
- NXP Nasdaq
- Market Cap
- TRML 598.9M
- NXP 699.7M
- IPO Year
- TRML N/A
- NXP N/A
- Fundamental
- Price
- TRML $47.65
- NXP $14.34
- Analyst Decision
- TRML Hold
- NXP
- Analyst Count
- TRML 12
- NXP 0
- Target Price
- TRML $47.04
- NXP N/A
- AVG Volume (30 Days)
- TRML 1.6M
- NXP 70.0K
- Earning Date
- TRML 11-06-2025
- NXP 01-01-0001
- Dividend Yield
- TRML N/A
- NXP 4.04%
- EPS Growth
- TRML N/A
- NXP N/A
- EPS
- TRML N/A
- NXP 0.54
- Revenue
- TRML N/A
- NXP N/A
- Revenue This Year
- TRML N/A
- NXP N/A
- Revenue Next Year
- TRML N/A
- NXP N/A
- P/E Ratio
- TRML N/A
- NXP $26.81
- Revenue Growth
- TRML N/A
- NXP N/A
- 52 Week Low
- TRML $11.56
- NXP $12.91
- 52 Week High
- TRML $47.70
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- TRML 94.40
- NXP 75.05
- Support Level
- TRML $22.31
- NXP $13.93
- Resistance Level
- TRML $47.69
- NXP $14.55
- Average True Range (ATR)
- TRML 1.15
- NXP 0.09
- MACD
- TRML 2.54
- NXP 0.04
- Stochastic Oscillator
- TRML 99.80
- NXP 67.19
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.